ClinicalTrials.gg

Program

amrecibart

Its studies are mostly in Venous Thromboembolism · Atrial Fibrillation · Kidney Failure, Chronic · Hemorrhage, led by Regeneron Pharmaceuticals.

Furthest: phase 3, since Feb 18, 20268 company-led studies, 4 open or runningNext primary completion: Feb 9, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals84 open or runningphase 3since Feb 18, 2026Oct 19, 2021Feb 9, 2027phase 2 · NCT07175428

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 19, 2021First study: phase 1 study in Healthy VolunteersFirst studyNCT05102136 · 56 enrolled · Belgium
  2. Nov 8, 2022Phase 2 study in Venous ThromboembolismNCT05618808 · 373 enrolled · Belgium, Bulgaria, Canada and more
  3. Mar 1, 2024Phase 2 study in Venous ThromboembolismNCT06299111 · 195 enrolled · United States, Bulgaria, Canada and more
  4. May 30, 2024Phase 1 study in HemorrhageNCT06444178 · 224 enrolled · United Kingdom
  5. Sep 9, 2025Phase 2 study in Atrial FibrillationNCT07175428 · 1,200 planned · United States, Argentina, Brazil and more
  6. Feb 18, 2026Phase 3 study in Atrial FibrillationPhase 3 reachedNCT07430956 · 2,628 planned · United States, Canada
  7. Jul 6, 2026Phase 3 study in Venous ThromboembolismNCT07697599 · 1,908 planned · Georgia
  8. Aug 6, 2026Phase 1 study in Kidney Failure, ChronicNCT07759167 · 36 planned · Belgium

Ahead

  1. Feb 9, 2027Primary completion: phase 2 study in Atrial FibrillationNCT07175428
  2. Apr 2, 2027Primary completion: phase 1 study in Kidney Failure, ChronicNCT07759167
  3. Mar 28, 2029Primary completion: phase 3 study in Atrial FibrillationNCT07430956
  4. Jun 25, 2029Primary completion: phase 3 study in Venous ThromboembolismNCT07697599

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07759167Kidney Failure, Chronic · Belgium1RecruitingApr 2, 202736
NCT07697599Venous Thromboembolism · Georgia3RecruitingJun 25, 20291,908
NCT07430956Atrial Fibrillation · United States, Canada3RecruitingMar 28, 20292,628
NCT07175428Atrial Fibrillation · United States, Argentina, Brazil and more2RecruitingFeb 9, 20271,200
NCT06444178Hemorrhage · United Kingdom1CompletedApr 7, 2025224
NCT06299111Venous Thromboembolism · United States, Bulgaria, Canada and more2CompletedMar 27, 2026195
NCT05618808Venous Thromboembolism · Belgium, Bulgaria, Canada and more2CompletedMay 27, 2024373
NCT05102136Healthy Volunteers · Belgium1CompletedApr 4, 202356

How it is read

Names in the registry

  • “REGN9933”, 8 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.